Equities Research Analysts’ Updated EPS Estimates for November, 14th (APD, BAP, CMTA, DB, DHT, EDR, EVHC, FEYE, GMED, GSC)

Equities Research Analysts’ updated eps estimates for Tuesday, November 14th:

Air Products and Chemicals (NYSE:APD) was upgraded by analysts at HSBC from a hold rating to a buy rating.

Credicorp (NYSE:BAP) was downgraded by analysts at HSBC from a buy rating to a hold rating.

Clementia Pharmaceuticals (NASDAQ:CMTA) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $26.00 price target on the stock.

Deutsche Bank AG (NYSE:DB) was upgraded by analysts at HSBC Holdings plc to a buy rating.

DHT Holdings (NYSE:DHT) was given a $7.00 price target by analysts at Maxim Group. The firm currently has a buy rating on the stock.

Education Realty Trust (NYSE:EDR) was given a $44.00 price target by analysts at B. Riley. The firm currently has a buy rating on the stock.

Envision Healthcare Corporation (NYSE:EVHC) was given a $40.00 target price by analysts at KeyCorp. The firm currently has a buy rating on the stock.

FireEye (NASDAQ:FEYE) had its neutral rating reaffirmed by analysts at Wedbush. The firm currently has a $14.00 price target on the stock.

Globus Medical (NYSE:GMED) had its buy rating reiterated by analysts at Gabelli.

Golden Star Resources (TSE:GSC) (NYSE:GSS) had its sector perform rating reiterated by analysts at Scotiabank. The firm currently has a C$1.20 target price on the stock.

Liberty Global PLC (NASDAQ:LILA) was upgraded by analysts at HSBC from a reduce rating to a hold rating.

Linde Aktiengesellschaft (OTCMKTS:LNEGY) was downgraded by analysts at HSBC from a buy rating to a hold rating.

Loxo Oncology (NASDAQ:LOXO) was upgraded by analysts at JMP Securities from a market perform rating to an outperform rating. They currently have $95.00 target price on the stock, up from their previous target price of $77.18.

Neurocrine Biosciences (NASDAQ:NBIX) was given a $85.00 target price by analysts at Oppenheimer Holdings, Inc.. The firm currently has a buy rating on the stock.

Roku (NASDAQ:ROKU) was downgraded by analysts at UBS AG from a market perform rating to an underperform rating.

Stepan (NYSE:SCL) was upgraded by analysts at Scotiabank from an underperform rating to a sector perform rating. They currently have $32.00 price target on the stock.

Zebra Technologies Corporation (NASDAQ:ZBRA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Zebra Technologies Corporation and its wholly-owned subsidiaries design, manufacture and support a broad range of direct thermal and thermal transfer bar code label printers, receipt printers, instant-issuance plastic card printers and secure identification printing systems, related accessories, and support software. The company markets its products worldwide principally to manufacturing and service organizations for use in automatic identification, data collection, and personal identification systems. “

Olympic Steel (NASDAQ:ZEUS) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $22.00 target price on the stock. According to Zacks, “OLYMPIC STEEL INC. is a specialized steel service center that processes and distributes flat- rolled carbon, stainless and tubular steel products. Co. operates as an intermediary between steel producers and manufacturers that require processed steel for their operations. Co. purchases flat-rolled steel typically from steel producers and responds to its customers’ needs by processing steel to customer specifications and by providing critical inventory and just-in-time delivery services. “

Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $7.75 price target on the stock. According to Zacks, “Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada. “

Receive News & Ratings for Air Products and Chemicals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Air Products and Chemicals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply